Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study
Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study
复制标题
DOI：
10.1016/j.jaci.2012.07.028
复制
发表时间：
2013-01-01
影响因子：
14.2
通讯作者：
Hafner, Roderick P.
中科院分区：
文献类型：
--
作者：
Patel, Deepen;Couroux, Peter;Hafner, Roderick P.
背景：变应性鼻结膜炎是一种越来越常见的发病来源，对猫的敏感性占疾病负担的10%至15%。对猫过敏也是患哮喘的一个主要危险因素。目的：我们试图探讨一种新型的Fel - d1衍生肽抗原脱敏（cat - pad）在猫过敏性鼻结膜炎患者接受标准化过敏原攻击后开始治疗1年后的治疗效果的持久性。方法：在一项随机、双盲、安慰剂对照、平行组临床试验中，受试者在接受2种不同cat - pad治疗前后，在3个月的时间里，进入环境暴露室，暴露于猫过敏原。临床疗效评估为治疗开始后18至22周和50至54周总鼻结膜炎症状评分的变化。结果：Cat-PAD每隔4周给予4次6 nmol剂量的治疗比每隔2周给予8次3 nmol剂量的治疗效果更好。治疗开始1年后，6 nmol的治疗效果持续，与3 nmol （P = 5.0342）和安慰剂（P = 5.0104）有显著差异。治疗1年后鼻、眼症状均有明显改善。结论：短疗程cat - pad可改善猫过敏患者鼻结膜炎的眼部和鼻部症状，治疗开始后1年仍有效果。[J] .中华过敏症杂志，2013;31(1):103- 109。
Background: Allergic rhinoconjunctivitis is an increasingly common source of morbidity, with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a major risk factor for the development of asthma.Objectives: We sought to probe the persistence of the treatment effect of a novel Fel d 1-derived peptide antigen desensitization (Cat-PAD) 1 year after the start of treatment in subjects with cat allergy-induced rhinoconjunctivitis after standardized allergen challenge.Methods: In a randomized, double-blind, placebo-controlled, parallel-group clinical trial, subjects attended an environmental exposure chamber in which they were exposed to cat allergen before and after treatment with 2 different regimens of Cat-PAD over a 3-month period. Clinical efficacy was assessed as a change in total rhinoconjunctivitis symptom scores 18 to 22 weeks and 50 to 54 weeks after the start of treatment.Results: Treatment with Cat-PAD showed greater efficacy with 4 administrations of a 6-nmol dose 4 weeks apart than with 8 administrations of a 3-nmol dose 2 weeks apart. The treatment effect of 6 nmol persisted 1 year after the start of treatment and was significantly different from that of 3 nmol (P = 5.0342) and placebo (P = 5.0104). The treatment effect was apparent on both nasal and ocular symptoms at 1 year.Conclusions: A short course of Cat-PAD improves the ocular and nasal components of rhinoconjunctivitis symptoms in subjects with cat allergy, with the treatment effect persisting 1 year after the start of treatment. (J Allergy Clin Immunol 2013;131:103-9.)